The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

The new breast cancer screening guidelines are not enough to save Black women

A breast surgical oncologist and breast radiologist weigh in

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The U.S. Preventive Services Task Force’s new guidelines to offer mammography from age 40 will save many lives.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Vivian Jolley Bea, MD
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Kemi Babagbemi, MD
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment. 
Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. 
Byline
Vivian Jolley Bea, MD
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Kemi Babagbemi, MD
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account